Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genetic erosion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Genetic erosion. Displaying page 1 of 1.
    EudraCT Number: 2014-002945-23 Sponsor Protocol Number: MT203-2004 Start Date*: 2015-02-18
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs A...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Prematurely Ended) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001729-25 Sponsor Protocol Number: RA0055 Start Date*: 2012-03-05
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical re...
    Medical condition: Early active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) HU (Completed) ES (Completed) CZ (Completed) AT (Completed) SE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007539-14 Sponsor Protocol Number: D1710C00009 Start Date*: 2008-05-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administere...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) MT (Completed) LV (Completed) IT (Completed) PL (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000840-75 Sponsor Protocol Number: D4920C00002 Start Date*: 2020-09-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Infl...
    Medical condition: Myocardial Infarction (MI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10030272 Old myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002322-20 Sponsor Protocol Number: PA0010 Start Date*: 2019-06-26
    Sponsor Name:UCB Biopharma SRL
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) HU (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020744-35 Sponsor Protocol Number: D4300C00002 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Re...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) LV (Completed) LT (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001996-35 Sponsor Protocol Number: GS-US-431-4566 Start Date*: 2020-03-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic ...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) PL (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020745-27 Sponsor Protocol Number: D4300C00003 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Respon...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:31:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA